Abstract: Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.

Abstract: The invention is in general directed to acid-sensitive linkers, and methods of use thereof, such as, for example, in drug delivery methods.

Abstract: This invention provides novel liver targeting agents and their synthetic methods. A liver targeting agent, with a lysine based nitrilotriacetic acid structure as backbone which acquires multivalency with saccharide groups, to bind with a galactosamine chain or lactose chain is disclosed. In particular, only one amino acid L-lysine is involved to provide trivalency. All carboxyl groups in N?-benzyloxycarbonyl-N?-dicarboxymethyl-L-lysine can be conjugated with three glycosides of ahGalNAc or ahLac in one step. This invention also provides a hexa-lactoside. In particular, the TFA-AHA-Asp was used to conjugate 2 molecules of NTA(ahLac)3. This invention also provides a method for adding a spacer between NTA and DTPA. The extended hepatocyte-specific glyco-ligand has higher 111In-radiolabelling yield than those non-extended.

Abstract: Synergistic anti-adipogenic and pro-lipolytic compositions for the prevention and amelioration of adipogenesis and lipolysis mediated diseases, comprising at least two extracts selected from enriched demethylated curcuminoids obtained from Curcuma longa, Moringa oleifera and Murraya koenigii. The anti-adipogenic and pro-lipolytic compositions optionally contain one or more anti-obesic agents. These compositions are useful for preventing anti-inflammatory and free radical mediated diseases.

Abstract: The present invention relates to lipoteichoic acid T for use in treating pleural effusion or pneumothorax. The present invention also relates to the use of lipoteichoic acid T (LTA-T) in the manufacture of a medicament for treating pleural effusion or pneumothorax. The present invention also relates to a kit comprising a pharmaceutical composition comprising lipoteichoic acid T and instructions indicating that the composition is for use as a pleurodesis agent. In addition, the present invention relates to a method of treating pleural effusion or pneumothorax comprising administration of lipoteichoic acid T to a subject.

Abstract: The invention encompasses novel compounds and pharmaceutically acceptable salts thereof and compositions including therapeutically or prophylactically effective amounts of such compounds or pharmaceutically acceptable salts thereof. The invention also encompasses methods for treating or preventing diseases and disorders associated abnormal cell growth, for example, treating or preventing cancer or tumor growth, which methods include administering to a mammal in need thereof a composition comprising a therapeutically or prophylactically effective amount of a compound of the invention or a pharmaceutically acceptable salt thereof.

Abstract: The invention provides methods of purifying Rebaudioside D from the Stevia rebaudiana Bertoni plant extract along with Rebaudioside A. The methods are useful for producing high purity Rebaudioside D and Rebaudioside A. The invention further provides a low-calorie carbonated lemon-flavored beverage containing the purified Rebaudioside D and a process for making the low-calorie carbonated lemon-flavored beverage containing the purified Rebaudioside D.

Abstract: The invention relates to special nucleosides, for example, a nucleoside of the formula I, wherein R1-R5 are as described herein, and also to drugs which contain these nucleosides. Furthermore, the invention relates to the use of such nucleosides in a method for suppressing or reducing the formation of resistance in the case of cytotstatic treatment of a cancer patient.

Abstract: The present invention provides compositions for performing assays of enzyme activity associated with lysosomal storage diseases. The invention further provides methods for determining enzyme activity, and methods for the screening for lysosomal storage disease in an individual.

Abstract: An NK1 receptor antagonist composition of the present invention uses maltooligosaccharide having an NK1 receptor antagonistic activity as an active ingredient. A suitable amount of the maltooligosaccharide to be blended in the NK1 receptor antagonist composition of the present invention is 0.000001 to 70% by weight. The NK1 receptor antagonist composition of the present invention is prepared for use into various forms of external agents, internal medicines, foods and beverages by blending various materials as the ingredients other than the active ingredient. The NK1 receptor antagonist composition of the present invention has high safety for being used for pharmaceuticals and has satisfactory therapeutic effects.

Abstract: A use of an anti-inflammatory polysaccharides composition comprising fucans and galactans to inhibit the release of one or more of IL-8, PGE2 and VEGF by a cell activated during an inflammatory process and an anti-inflammatory composition comprising a ratio of brown algae fucans/red algae galactans of between about 2.5/1 (w/w) to about 40/1 (w/w), the galactans having a molecular weight higher than about 100 kDa, and the fucans having a molecular weight between about 0.1 kDa and 100 kDa.

Abstract: Disclosed herein is a cancer sensitizer comprising glucosamine, a glucosamine derivative, or a salt thereof. When administered to patients with cancer, the cancer sensitizer functions to sensitize cancer cells to anticancer agents without producing side effects, thereby increasing the therapeutic efficiency of chemotherapy.

Abstract: C-glycoside keto-amide derivatives, including C-glycoside keto-hydrazones and C-glycoside keto-oximes, may be prepared from plant or animal lipids and saccharides. These C-glycoside keto-amide derivatives are of the formula: wherein: R is a saccharide; Y is independently selected from H or a halogen; m is an integer greater than or equal to 1; X is NH (as in C-glycoside keto-hydrazones) or O (as in C-glycoside keto-oximes); and R2 is an acyl moiety derived from any lipid fatty acid of the formula —C(O)—R3, wherein R3 is a C5 to C22 straight or branched chain hydrocarbon which may be saturated or unsaturated. These C-glycoside keto-amide derivatives have potential applications as surfactants, detergents, liposomes, and bilayers.

Abstract: A method for producing crystalline sulphated cellulose II materials with relatively low degree of polymerization from spent liquors of sulphuric acid (H2SO4) hydrolysis of cellulose has been discovered. The method involves: 1) separating the spent liquors from the hydrolysed, acid-insoluble, cellulose I materials by dilution from, for example, a 64% H2SO4 hydrolysis medium to a residual sulphuric acid concentration of 10-50% with 0-40% H2SO4, followed by settling (or centrifuging) and decanting; 2) adding the diluted spent liquors to water or heating the diluted spent liquors at 30-80° C. for ?48 h; and 3) recovering the recrystallized sulphated cellulose II materials with relatively low degree of polymerization either by filtration and washing or by washing and freeze drying. The method can be used to concurrently produce both crystalline, sulphated cellulose I and the crystalline, sulphated cellulose II materials.

Abstract: The invention provides methods of purifying Rebaudioside D from the Stevia rebaudiana Bertoni plant extract along with Rebaudioside A. The methods are useful for producing high purity Rebaudioside D and Rebaudioside A. The high purity Rebaudiosides are useful as non-caloric sweeteners in edible and chewable compositions such as any beverages, confectionaries, bakeries, cookies, chewing gums, and alike.

Abstract: Methods of treating glioblastoma and pancreatic cancer are provided by the administration of a therapeutically effective amount of a iodo-hexose compound to a subject in need thereof. The subject disclosure includes methods of treating glioblastoma and pancreatic cancer comprising the administration of a therapeutically effective amount of a 2-deoxy-2-iodo-D-hexose compound including 2-deoxy-2-iodo-D-mannose, 2-deoxy-2-iodo-D-glucose, 2-deoxy-2-iodo-D-galactose, and/or 2-deoxy-2-iodo-D-talose to a subject in need thereof.

Abstract: The invention provides a pseudoglycolipid effective for cancer treatment and the like and a novel synthesis intermediate therefor, as well as a medicament containing the pseudoglycolipid and the like. The inventive compound is represented by the formula (1), or a salt thereof, wherein each symbol is as defined in the specification.

Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.

Abstract: The disclosure provides novel topical antiviral pharmaceutical compositions comprising one or more antiviral compounds and 2-deoxy-D-glucose in the form of lip-balms, creams and ointments. A specific embodiment discloses a lip-balm composition comprising acyclovir and 2-deoxy-D-glucose.

Abstract: Disclosed herein are brown algae-derived fucoidan and in particular a method for degrading fucoidan to a low-molecular weight so that fucoidan as sparingly-degradable polysaccharide (M.W. 3,000,000 to 5,000,000) can be more efficiently extracted from brown algae and it can be absorbed in the human body. The method comprises preparing a fucoidan extract containing as much fucoidan as possible from brown algae selected from Hizikia fusiforme, Undaria pinnatifida, Laminaria saccharina, Ecklonia cava, Cladosiphon Okamuranus and Nemacystus decipiens, and low-molecularizating the fucoidan extract using Vibrio halioticoli (Accession No. KCTC 10998BP) and a probiotic mixture containing Streptococcus faecalis, Bacillus mesentericus, Clostridium butyricum, and glycosyltransferase thereof. According to the method, fucoidan can be efficiently degraded to a low molecular weight using microorganisms so that it can be absorbed in the human body.